Tamtam Try Tamtam free
Dana-Farber Cancer Institute logo

Dana-Farber Cancer Institute account plan

Expert compassionate cancer care

At a glance

Dana-Farber Cancer Institute is a Boston not-for-profit cancer research and treatment center with FY2025 operating revenues of $3,922,850 thousand.

Dana-Farber Cancer Institute is a comprehensive cancer center for basic and clinical cancer research and treatment, a Massachusetts not-for-profit 501(c)(3) that primarily serves patients in the New England region. It earns revenue from patient care, research (grants, contracts, licenses and research gifts) and philanthropy; its inpatient hospital currently sits inside Brigham & Women's Hospital. In FY2025 (year ended September 30, 2025) total operating revenues were $3,922,850 thousand against $3,438,436 thousand in FY2024, with operating income of $102,353 thousand. It is building its own 300-bed cancer hospital in the Longwood Medical Area. Benjamin L. Ebert is President and CEO.

Business units

Strategic priorities

New 300-bed cancer hospital
A 300-bed cancer hospital in the Longwood Medical Area, owned and operated by Dana-Farber, received final Massachusetts DPH approval on May 19, 2025; its debt financing is expected in 2026.
Clinical collaboration with BIDMC
The hospital is central to a clinical collaboration with Beth Israel Deaconess Medical Center and Harvard Medical Faculty Physicians for adult cancer patients.
Protect research funding
About one-third of research funding comes from the federal government; the CEO has been engaging Congress, citing bipartisan support for cancer research.
AI in care and research
AI is to take care of administrative tasks, improve diagnostic accuracy in radiology and pathology, and transform translational research with large language models.
Scientific bets
Early detection and interception, drugs against "undruggable" targets such as KRAS, and extra support for rare and pediatric cancers.

Investments and deals

Hospital construction
Additions to property, plant and equipment were $165,584 thousand in FY2025 and construction-in-progress rose to $206,229 thousand.
Hospital financing hedges
Swaptions with notional amounts of $1,191,644 thousand with JPMorgan and $611,094 thousand with Goldman Sachs hedge the anticipated hospital debt financing.
Global oncology
Dana-Farber Global Oncology is the entity through which the Institute is engaging in work in China.

Challenges and risks

Federal research funding uncertainty
Federal funding freezes hit Harvard University and Harvard Medical School; Dana-Farber says it had suffered no cuts but is preparing for various scenarios.
Complex reimbursement rules
Medicare and Medicaid rules are complex and subject to interpretation, so recorded estimates may change by a material amount.
Interest rate and investment risk
Variable-rate bonds, swaps and swaptions carry interest rate risk, and $1,759,967 thousand sits in non-marketable hedge and private equity funds.
Grant competition
Less than 10 percent of the grants Dana-Farber submits to the National Cancer Institute are funded.

What leadership says

“The promise that AI can accelerate the development of new cancer drugs and accelerate scientific research broadly is absolutely thrilling.”

Benjamin L. Ebert, President and CEO · The ASCO Post interview, March 25, 2026

“AI in oncology isn't a way of replacing humans. It's a way of taking care of some of the administrative tasks that allow us to have more human interactions with our patients.”

Benjamin L. Ebert, President and CEO · The ASCO Post interview, March 25, 2026

“I'm an absolute believer that this is the most promising time for cancer research and for new therapeutics for cancer that we've ever had.”

Benjamin Ebert, President and CEO · Walker Webcast, April 30, 2025

Where a supplier can help

New hospital fit-out
The 300-bed Longwood hospital, with construction-in-progress already rising, creates demand for medical equipment, IT infrastructure and facility services.
AI for radiology, pathology and admin
The CEO's AI priorities (administrative tasks, diagnostic accuracy, large language models in translational research) fit clinical AI and data platform vendors.
Research operations and grants management
With research funded by federal grants, non-federal grants and gifts, and federal funding uncertain, grant management and research administration tools can help.
Clinical trial partnerships
Pharma and biotech fund part of the research through clinical trials, which suits trial sponsors and clinical research service providers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Dana-Farber Cancer Institute?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Dana-Farber Cancer Institute

What does Dana-Farber Cancer Institute do?

It is a comprehensive cancer center in Boston dedicated to basic and clinical cancer research and treatment, primarily serving patients in New England.

What is Dana-Farber's revenue?

Total operating revenues were $3,922,850 thousand in FY2025 (year ended September 30, 2025), of which net patient service revenue was $3,012,853 thousand.

Who leads Dana-Farber?

Benjamin L. Ebert, MD, PhD, is President and CEO; he also directs Dana-Farber/Harvard Cancer Center.

What is Dana-Farber's strategy?

Building its own 300-bed cancer hospital in the Longwood Medical Area as part of a clinical collaboration with Beth Israel Deaconess Medical Center, while investing in AI, early detection and new therapies.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)